CCL

Összesen 28 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM075353
Első szerző:Biró Orsolya (molekuláris biológus)
Cím:Relationship between cardiovascular diseases and circulating cell-free nucleic acids in human plasma / Orsolya Biró, Orsolya Hajas, Edina Nagy-Baló, Beata Soltész, Zoltan Csanádi, Bálint Nagy
Dátum:2018
ISSN:1752-0363 1752-0371
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Biomarkers in Medicine. - 12 : 8 (2018), p. 891-905. -
További szerzők:Hajas Orsolya (1987-) Nagy-Baló Edina (1985-) (kardiológus) Soltész Beáta (1987-) (molekuláris biológus) Csanádi Zoltán (1960-) (kardiológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM101421
035-os BibID:(cikkazonosító)4284 (scopus)85128130388 (wos)000785465100001
Első szerző:Buglyó Gergely (genetikus)
Cím:Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome / Gergely Buglyó, Jakub Styk, Ondrej Pös, Ádám Csók, Vanda Repiska, Beáta Soltész, Tomas Szemes, Bálint Nagy
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Lynch syndrome (LS) is an autosomal dominant inherited cancer predisposition disorder, which may manifest as colorectal cancer (CRC), endometrial cancer (EC) or other malignancies of the gastrointestinal and genitourinary tract as well as the skin and brain. Its genetic cause is a defect in one of the four key DNA mismatch repair (MMR) loci. Testing of patients at risk is currently based on the absence of MMR protein staining and detection of mutations in cancer tissue and the germline, microsatellite instability (MSI) and the hypermethylated state of the MLH1 promoter. If LS is shown to have caused CRC, lifetime follow-up with regular screening (most importantly, colonoscopy) is required. In recent years, DNA and RNA markers extracted from liquid biopsies have found some use in the clinical diagnosis of LS. They have the potential to greatly enhance the efficiency of the follow-up process by making it minimally invasive, reproducible, and time effective. Here, we review markers reported in the literature and their current clinical applications, and we comment on possible future directions.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Lynch syndrome
colorectal cancer
screening
liquid biopsy
circulating nucleic acids
biomarker
Megjelenés:International Journal Of Molecular Sciences. - 23 : 8 (2022), p. 4284. -
További szerzők:Styk, Jakub Pös, Ondrej (1990-) (biológus) Csók Ádám (1994-) (biológus) Repiska Vanda Soltész Beáta (1987-) (molekuláris biológus) Szemes, Tomas (1980-) (biológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM080605
035-os BibID:(cikkazonosító)E4119 (PMID)31450846 (scopus)85071765729 (wos)000486888400051
Első szerző:Dvorská, Dana
Cím:Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples / Dana Dvorská, Dušan Braný, Bálint Nagy, Marián Grendár , Robert Poka, Beáta Soltész, Marianna Jagelková, Katarína Zelinová, Zora Lasabová, Pavol Zubor, Zuzana Danková
Dátum:2019
ISSN:1661-6596 1422-0067
Megjegyzések:Ovarian cancer is a highly heterogeneous disease and its formation is affected by many epidemiological factors. It has typical lack of early signs and symptoms, and almost 70% of ovarian cancers are diagnosed in advanced stages. Robust, early and non-invasive ovarian cancer diagnosis will certainly be beneficial. Herein we analysed the regulatory sequence methylation profiles of the RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes by pyrosequencing in healthy, benign and malignant ovarian tissues, and corresponding plasma samples. We recorded statistically significant higher methylation levels (p < 0.05) in the CDH1 and PAX1 genes in malignant tissues than in controls (39.06 ? 18.78 versus 24.22 ? 6.93; 13.55 ? 10.65 versus 5.73 ? 2.19). Higher values in the CDH1 gene were also found in plasma samples (22.25 ? 14.13 versus 46.42 ? 20.91). A similar methylation pattern with positive correlation between plasma and benign lesions was noted in the CDH1 gene (r = 0.886, p = 0.019) and malignant lesions in the PAX1 gene (r = 0.771, p < 0.001). The random forest algorithm combining methylation indices of all four genes and age determined 0.932 AUC (area under the receiver operating characteristic (ROC) curve) prediction power in the model classifying malignant lesions and controls. Our study results indicate the effects of methylation changes in ovarian cancer development and suggest that the CDH1 gene is a potential candidate for non-invasive diagnosis of ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
liquid biopsy
pirosequencing
ovarian cancer
Megjelenés:International Journal of Molecular Sciences. - 20 : 17 (2019), p. 1-19. -
További szerzők:Braný, Dušan Nagy Bálint (1956-) (molekuláris genetikus) Grendar, Marian Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Soltész Beáta (1987-) (molekuláris biológus) Jagelková, Marianna Zelinová, Katarína Lasabova, Zora Zubor, Pavol Danková, Zuzana
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM113209
035-os BibID:(cikkazonosító)1904 (WoS)001039867600001 (Scopus)85166312107
Első szerző:Gombos Gréta
Cím:New Possible Ways to Use Exosomes in Diagnostics and Therapy via JAK/STAT Pathways / Gombos Gréta, Németh Nikolett, Pös Ondrej, Styk Jakub, Buglyó Gergely, Szemes Tomas, Danihel Ludovit, Nagy Bálint, Balogh István, Soltész Beáta
Dátum:2023
ISSN:1999-4923
Megjegyzések:Exosomes have the potential to be the future of personalized diagnostics and therapy. They are nano-sized particles between 30 and 100 nm flowing in the extracellular milieu, where they mediate cell-cell communication and participate in immune system regulation. Tumor-derived exosomes (TDEs) secreted from different types of cancer cells are the key regulators of the tumor microenvironment. With their immune suppressive cargo, TDEs prevent the antitumor immune response, leading to reduced effectiveness of cancer treatment by promoting a pro-tumorigenic microenvironment. Involved signaling pathways take part in the regulation of tumor proliferation, differentiation, apoptosis, and angiogenesis. Signal transducers and activators of transcription factors (STATs) and Janus kinase (JAK) signaling pathways are crucial in malignancies and autoimmune diseases alike, and their potential to be manipulated is currently the focus of interest. In this review, we aim to discuss exosomes, TDEs, and the JAK/STAT pathways, along with mediators like interleukins, tripartite motif proteins, and interferons.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
exosome
Megjelenés:Pharmaceutics. - 15 : 7 (2023), p. 1-17. -
További szerzők:Németh Nikolett (1995-) (biológus) Pös, Ondrej (1990-) (biológus) Styk, Jakub Buglyó Gergely (1980-) (genetikus) Szemes, Tomas (1980-) (biológus) Danihel, Ludovit Nagy Bálint (1956-) (molekuláris genetikus) Balogh István (1972-) (molekuláris biológus, genetikus) Soltész Beáta (1987-) (molekuláris biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM078520
035-os BibID:(PMID)31002856 (WoS)000466942100010 (Scopus)85064701689
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer / Keserű J. S., Soltész B., Lukács J., Márton É., Szilágyi-Bónizs M., Penyige A., Póka R., Nagy B.
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian tumor is one of the leading causes of cancer among women. Patients are diagnosed at an advanced stage, usually. There is a need for new specific and sensitive biomarkers. Mitochondrial DNA copy number change was observed in various cancers. Our aim was to detect mitochondrial DNA copy number in whole blood (wb-mtDNA) and in plasma (cell-free and exosome encapsulated mtDNA) in patients with serous epithelial ovarian tumor. DNA was isolated from EDTA blood and plasma obtained from 24 patients and 24 healthy controls. Exosomes were isolated from cell-free plasma, and exosome encapsulated DNA (exoDNA) was extracted. Quantitative-real-time PCR was performed with Human Mitochondrial DNA (mtDNA) Monitoring Primer Set. Kruskall?Wallis and Mann?Whitney U test were used for data analysis. Wb-mtDNA copy number was significantly different among healthy controls and patients in multiple comparison (p?=?0.0090 considering FIGO stage independently, and p?=?0.0048 considering early- and late-stage cancers). There was a significant decrease among early-stage, all advanced stage and all cancer patients (FIGO I: 32.5?±?8.3, p?=?0.0061; FIGO III?+?IV: 37.2?±?13.7 p?=?0.0139; FIGO I?+?III?+?IV: 35.6?±?12.2, p?=?0.0017) or FIGO III patients alone (32.8?±?5.6, p?=?0.00089) compared to healthy controls. We found significant increase in copy number in exosomal mtDNA in cancer patients (236.0?±?499.0, p?=?0.0155), advanced-stage cancer patients (333.0?±?575.0, p?=?0.0095), of FIGO III (362.0?±?609.2, p?=?0.0494), and FIGO IV (304.0?±?585.0, p?=?0.0393) patients alone but not in samples of FIGO I patients (10.0?±?3.5, p?=?0.3907). In multiple comparison the increase was significant considering early- and late-stage cancers (p?=?0.0253). Cell-free mtDNA copy numbers were not increased significantly. We found the highest copy number of mtDNA in exosomes, followed by plasma and peripheral blood in late-stage cancer patients. We observed significant difference in wb-mtDNA copy number between healthy controls and both early- and late-stage cancer patients.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Cell-free mtDNA
Exosomal mtDNA
Mitochondrial DNA
Serous ovarian cancer
Megjelenés:Journal of Biotechnology. - 298 (2019), p. 76-81. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Márton Éva (1992-) (biológus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM074284
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Correlation of plasma mitochondrial DNA copy number and status of ovarian cancer patients / Judit Keserű, Beáta Soltész, János Lukács, Róbert Póka, Bálint Nagy
Dátum:2018
Megjegyzések:Introduction: Mitochondria are important organelles in ATP synthesis of cells in aerobic conditions, and are involved in various different cell processes like cell proliferation, and apoptosis. Their copy number variations were connected to many different pathological conditions like development of many types of cancer, e.g. ovarian cancer. That is why we measured the mtDNA copy numbers in the plasma in ovarian cancer patients and healthy controls.Materials and methods: We involved 53 healthy controls (avarage age 57.45?10.61 years) and 24 ovarian cancer patients (average age 61.33?12.72 years) in the study. Blood was drawn into EDTA tubes and plasma was separated by centrifugations. MtDNA copy numbers were determined by Human Mitochondrial DNA (mtDNA) Monitoring Primer Set kit (Takara, Japan) with real-time PCR.Results: The mtDNA copy number was 43.55?13.69 in the healthy control group. We divided the ovarian cancer patients into groups according to their FIGO classification and their cancer stage. The copy numbers were the followings: FIGO I. (early-stage ovarian cancer) 32?8.27; FIGO III. and IV (advanced-stage ovarian cancer) 37.19?13.75 (FIGO III. 33?5.66; FIGO IV. 42?18.87). Student's unpaired t-test was performed. No significant difference was found among the early-stage and advanced-stage patients or control group and advanced stage patients (p=0.3740 and p=0.1084, respectively) but significant difference was found among control group and early-stage patients (p=0.0290) in the plasma cell-free mtDNA copy numbers.Conclusion: We determined the cell-free mtDNA copy numbers in the plasma of ovarian cancer patients and healthy controls and we found significant difference among control group and early-stage patients. We plan to extend the study to more ovarian cancer patients and also we plan exosome encapsulated mtDNA measurements.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
mitochondrial DNA
ovarian cancer
cell-free mtDNA
Megjelenés:Biomedical Papers. - 162 : Suppl. 1 (2018), p. S11. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM073381
035-os BibID:(cikkazonosító)E-P18.36 (WoS)000489312608202
Első szerző:Keserű Judit (molekuláris genetikus)
Cím:Determination of miR-196a Single Nucleotide Polymorphism (SNP) with melting-curve analysis in the population of patients with ovarian cancer / J. S. Keserű, J. Lukács, B. Soltész, K. Szirák, Z. Birkó, A. Penyige, B. Nagy, R. Póka
Dátum:2018
ISSN:1018-4813 1476-5438
Megjegyzések:Introduction: miRNA molecules are short, non-coding sequences regulating gene expression after transcription. They are important in the development, progression and treatability of tumours. Single Nucleotide Polymorphism (SNP) is the most frequent type of genetic polymorphism. That is true also for miRNAs and their polymorphisms can cause alterations in the gene expression profile. miR-196a was also linked to the genesis of different tumours.Aim: Search for correlation between miR-196a polymorphism and development of ovarian cancer.Materials and Methods: 75 patients with ovarian cancer and 75 healthy persons were investigated. 15-16 mL blood anticoagulated with EDTA was drawn. DNA was isolated with silica absorption method and the melting curve of PCR products generated with LightSnip kit (TibMolbiol, Berlin, Germany) developed for miR-196a (rs11614913) SNP was determined by LightCycler 96 equipment. Allele and genotype frequencies were specified and Student t-test was applied for statistical analysis of data.Results: The Tm of PCR products were 55.5?C for T allele and 62.6?C for C allele with melting-curve analysis. T allele occurred in 32.66% in population of patients and in 40.66% in control group. Genotypes among control persons were 18.66% for TT, 44.0% for TC, and 37.33% CC, while in case of patients these frequencies were 12.0%, 41.33%, and 46.66%, respectively (p=0.3815).Conclusion: miR-196a influences the expression of 684 genes, it requires further complex investigation, whether it is involved in the development of ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
ovarian cancer
miR-196a
SNP
Megjelenés:European Journal of Human Genetics. - 26 : Suppl. (2018), p. 1. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Soltész Beáta (1987-) (molekuláris biológus) Szirák Krisztina (1973-) (molekuláris genetikus) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM078797
035-os BibID:(PMID)30904593 (WoS)000464978100008 (Scopus)85063796275
Első szerző:Lukács János (szülész-nőgyógyász, genetikus)
Cím:Identification of miR-146a and miR-196a-2 single nucleotide polymorphisms at patients with high-grade serous ovarian cancer / János Lukács, Beáta Soltész, András Penyige, Bálint Nagy, Róbert Póka
Dátum:2019
ISSN:0168-1656
Megjegyzések:MicroRNAs play an essential role in the regulation of gene expression and tumor development. Single nucleotide polymorphism (SNP) can be observed in miRNAs and could influence gene expression. We aimed to identify miR-146a rs2910164 and miR-196a-2 rs11614913 polymorphisms in ovarian cancer patients and controls. 75 patients and 75 controls were involved. DNA was isolated from blood samples. MiR-146a rs2910164 and miR-196a-2 rs11614913 were determined by LightSnip kit. We used melting curve analysis for allele classification. Network analysis was made to find common target genes. We detected 72.67% G allele frequency of miR-146a rs2910164 in controls and 82.00% in patients group (p?=?0,053). GG, GC and CC genotypes occurred with 53.33%, 38.67% and 8.00% among controls, with 65.33%, 33.33% and 1.33% among patients, (p?=?0.0917). Allele C of miR-196a-2 rs11614913 occurred in 59.33% of controls and in 67.33% of patients (p?=?0.15). CC, CT and TT genotypes occurred with 37.33%, 44.00%, and 18.67% frequency in controls, with 46.67%; 41.33% and 12.00% in patients (p?=?0.3815). Network analysis found ATG9A, LBR, MBD4 and RUFY2 genes to be targets for both miRNAs. SNPs of miR-146a and miR-196a-2 showed no significant differences between patients and controls. More investigations are required to clarify the exact role of these SNPs in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Ovarian cancer
SNP
miR-146a
miR-196a-2
miRNA
Megjelenés:Journal Of Biotechnology. - 297 (2019), p. 54-57. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM072790
035-os BibID:(WoS)000423235202023
Első szerző:Lukács János (szülész-nőgyógyász, genetikus)
Cím:Analysis of mir-196a, mir-146a and two mir193b single nucleotide polymorphism in ovarian cancer patients / J. Lukacs, B. Soltesz, B. Nagy, R. Poka
Dátum:2017
ISSN:1048-891X
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:International Journal Of Gynecological Cancer. - 27 : Suppl. 4. (2017), p. 1581. -
További szerzők:Soltész Beáta (1987-) (molekuláris biológus) Nagy Bálint (1956-) (molekuláris genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM091613
035-os BibID:(WoS)000632094300001 (Scopus)85101520969
Első szerző:Márton Éva (biológus)
Cím:Comparative Analysis of Cell-Free miR-205-5p, let-7f-5p, and miR-483-5p Expression in Ovarian Cell Cultures and Plasma Samples of Patients with Ovarian Cancer / Éva Márton, Alexandra Varga, Beáta Soltész, András Penyige, János Lukács, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2021
Megjegyzések:The term liquid biopsy reveals a non-invasive diagnostic method that might be based on the quantification of cell-free microRNAs in body fluids. However, the identification of candidates for liquid biopsy is challenging. Our aim was to compare the cell-free expression of miR-483-5p, miR-205-5p, and let-7f-5p in ovarian cell cultures and plasma samples of patients with ovarian cancer. Both the intracellular and cell-free expression of miR-205-5p and let-7f-5p proved to be higher in the Estrogen Receptor ? (ER?) expressing PEO1 cell-line than in the estrogen non-sensitive A2780. Moreover, the expression of let-7f-5p was up-regulated in response to estradiol exposure that was diminished after the addition of an ER? selective antagonist. MiR-483-5p had lower intracellular and cell-free expression in PEO1. All these miRNAs had detectable expression level in plasma samples, among which miR-205-5p proved to be overexpressed in the plasma samples of patients with ovarian tumors compared to healthy controls and possessed an acceptable diagnostic potential with ROC-AUC 0.683 (95% CI 0.57?0.795). Functional annotation clustering of the target genes of miR-205-5p revealed several clusters involved in cancer development. We suggest that miR-205-5p might be a promising biomarker candidate in ovarian cancer that should be further analyzed in larger sample size.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
microRNA
ovarian cancer
liquid biopsy
Megjelenés:Applied Sciences-Basel. - 11 : 4 (2021), p. 1-10. -
További szerzők:Beke-Varga Alexandra Edit (1994-) (molekuláris biológus) Soltész Beáta (1987-) (molekuláris biológus) Penyige András (1954-) (molekuláris genetikus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Pályázati támogatás:ÚNKP-20-3
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM078164
035-os BibID:(PMID)30953675 (WoS)000464978100009 (Scopus)85063866299
Első szerző:Márton Éva (biológus)
Cím:Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer / Éva Márton, János Lukács, András Penyige, Eszter Janka, Lídia Hegedüs, Beáta Soltész, Gábor Méhes, Róbert Póka, Bálint Nagy, Melinda Szilágyi
Dátum:2019
ISSN:0168-1656
Megjegyzések:Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n=28) or non-malignant (n=12) ovarian tumors and disease-free healthy volunteers (n=60) by qRT-PCR. The expression levels of miR200a, miR200b, miR200c, miR141, miR429, miR203a, miR34b (p<0.001) and miR34a (p<0.01) were significantly higher in the malignant samples than in healthy controls. MiR203a, miR141 (p<0.01), miR200a and miR429 (p<0.05) levels were also higher in malignant compared to non-malignant samples. ROC-AUC was the highest in the case of miR200c: 0.861 (95%CI=0.776-0.947). Spearman's rank correlation analysis revealed positive correlation between the plasma levels of the studied miRNAs that was the highest between miR200b and miR200c (rs = 0.774; p<0.001). Target analysis also suggested tight interaction between these miRNAs in the regulation of cancer development. The agreement of diagnostic tests based on miRNA levels and the standard CA125 or HE4 was weak according to Cohen's kappa values. We conclude that miR200 family members, miR34b and miR203a might be promising complementary biomarkers in ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
petefészekrák
miRNS
miR200
miR34
miR203
CA125
HE4
Megjelenés:Journal of Biotechnology. - 297 (2019), p. 58-65. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Penyige András (1954-) (molekuláris genetikus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Hegedüs Lídia Soltész Beáta (1987-) (molekuláris biológus) Méhes Gábor (1966-) (patológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM074290
Első szerző:Márton Éva (biológus)
Cím:Study the role of miR141 and miR429 in the diagnosis of epithelial ovarian cancer / Éva Márton, János Lukács, Réka Szabó, Beáta Soltész, Eszter Janka, Róbert Póka, Bálint Nagy, Melinda Szilágyi-Bónizs
Dátum:2018
Megjegyzések:Ovarian cancer is the most lethal form of gynecological malignancy that is mostly due to the difficulty of early diagnosis. Developing a fast, non-invasive diagnostic test would greatly facilitate the early detection and survival chances of ovarian cancer. Circulating miRNAs proved to be promising biomarkers in various cancers, including breast, prostate, pancreatic or colon cancer. However, only few publications focus on circulating miRNAs in ovarian cancer especially in European populations.Here we studied the expression levels of miR141 and miR429 in the plasma samples of healthy (n=17), and previously untreated epithelial ovarian carcinoma patients (n=17, FIGO stages III or IV) in a Hungarian cohort. The relative amount of miRNAs was detected by qRT-PCR.The expression levels of miR141 and miR429 proved to be higher in the malignant samples compared to the healthy donors (p<0.05). ROC-AUC proved to be good in the case of both miR141 (0.737, 95%CI=0.565-0.909) and miR429 (0.727, 95%CI=0.552-0.901). Sensitivity and negative predictive value were higher in the case of miR429(76.47% and 75%) than in the case of miR141 (64.71% and 68.42%). However, specificity and positive predictive value proved to be higher in the case of miR141 (76.47% and 73.33%) than in the case of miR429 (70.59% and 72.22%). Diagnostic accuracy was higher in the case of miR429 (73.53%) than in the case of miR141 (70.59%).We conclude that the miR200 family member miR141 and miR429 might be promising candidate biomarkers in the diagnosis of ovarian cancer. Further studies are needed to test our hypothesis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
miRNA
Wilms tumor
FFPE
Megjelenés:Biomedical Papers. - 162 : Suppl. 1 (2018), p. S17. -
További szerzők:Lukács János (1975-) (szülész-nőgyógyász, genetikus) Szabó Réka Soltész Beáta (1987-) (molekuláris biológus) Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3